Chondroitin Sulfate Inhibits Monocyte Chemoattractant Protein-1 Release From 3T3-L1 Adipocytes: A New Treatment Opportunity for Obesity-Related Inflammation?

Thomas V Stabler¹, Eulàlia Montell², Josep Vergés², Janet L Huebner¹ and Virginia Byers Kraus¹,3

¹Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.
²Pre-Clinical R&D Department, Bioibérica, S.A.U., Barcelona, Spain.
³Division of Rheumatology and Immunology, Duke University School of Medicine, Durham, NC, USA.

ABSTRACT: Monocyte chemoattractant protein-1 (MCP-1) overproduction from inflamed adipose tissue is a major contributor to obesity-related metabolic syndromes. 3T3-L1 embryonic fibroblasts were cultured and differentiated into adipocytes using an established protocol. Adipocytes were treated with lipopolysaccharide (LPS) to induce inflammation and thus MCP-1 release. At the same time, varying concentrations of chondroitin sulfate (CS) were added in a physiologically relevant range (10-200 µg/mL) to determine its impact on MCP-1 release. Chondroitin sulfate, a natural glycosaminoglycan of connective tissue including the cartilage extracellular matrix, was chosen on the basis of our previous studies demonstrating its anti-inflammatory effect on macrophages. Because the main action of MCP-1 is to induce monocyte migration, cultured THP-1 monocytes were used to test whether CS at the highest physiologically relevant concentration could inhibit cell migration induced by human recombinant MCP-1. Chondroitin sulfate (100-200 µg/mL) inhibited MCP-1 release from inflamed adipocytes in a dose-dependent manner (P < .01, 95% confidence interval [CI]: −5.89 to −3.858 at 100 µg/mL and P < .001, 95% CI: −6.028 to −3.996 at 200 µg/mL) but had no effect on MCP-1–driven chemotaxis of THP-1 monocytes. In summary, CS could be expected to reduce macrophage infiltration into adipose tissue by reduction in adipocyte expression and release of MCP-1 and as such might reduce adipose tissue inflammation in response to pro-inflammatory stimuli such as LPS, now increasingly recognized to be relevant in vivo.

KEYWORDS: Chondroitin sulfate, adipocytes, MCP-1, chemokines, LPS

Introduction
Monocyte chemoattractant protein-1 (MCP-1) is one of the key factors in the initiation of inflammation by inducing the migration of monocytes to inflammatory lesions via its chemotactic effect.¹ Once attracted to the lesion, monocytes differentiate into activated macrophages, which are the source of many inflammatory cytokines. Monocyte chemoattractant protein-1 is well known to play a critical role in the pathogenesis of type 2 diabetes and metabolic syndrome in association with abdominal obesity through the recruitment of monocytes by the increased expression of MCP-1 from adipocytes.² Cullberg recently demonstrated that lipopolysaccharide (LPS) is a potent stimulator of MCP-1 expression in the 3T3-L1 adipocyte cell line.³ One of the key stimuli for the upregulation of MCP-1 is the binding of activated nuclear factor κB (NF-κB) to the MCP-1 gene promoter in multiple cell types including THP-1 macrophages.⁴,⁵ Monocyte chemoattractant protein-1 may also play a role in nonalcoholic fatty liver disease and non-alcoholic steatohepatitis by its action on macrophages.⁶–⁸ Chondroitin sulfate (CS), a natural glycosaminoglycan of the cartilage extracellular matrix, has clinical benefit in symptomatic osteoarthritis but has never been tested in adipose tissue. Chondroitin sulfate exerts an anti-inflammatory activity and has positive effects on osteoarthritic chondrocytes, synoviocytes, and subchondral bone osteoblasts.⁹ In addition, we have recently published that CS can attenuate the monosodium urate crystal–mediated THP-1 macrophage inflammatory response reflected by reduced release of pro-inflammatory cytokines interleukin 1β and tumor necrosis factor α (TNF-α).¹⁰ We have also recently determined that the CS inhibitory effect is not acting at the inflammasome, but upstream, most likely by inhibiting activation of NF-κB,¹¹ as it has been described for other cell types.¹² We sought to determine whether CS had an inhibitory effect on MCP-1 release from LPS–stimulated adipocytes and/or blocked MCP-1–induced chemotaxis of inflammatory cells.

Methods
3T3-L1 adipocyte experiments
3T3-L1 mouse embryonic fibroblasts were obtained from ATCC (Manassas, VA, USA) and were grown to confluence in 5% CO₂ on COSTAR 24-well plates (Corning, Kennebunk, ME, USA) with a basal media of Dulbecco's Modified Eagle's
medium-high glucose containing 10% fetal bovine serum and 1% penicillin/streptomycin (media and supplements from Thermo Fisher, Waltham, MA, USA). Cells were induced to differentiate into adipocytes by the method of Zebisch et al. Briefly, at 2 days after confluence (day 1), the following were added to the basal media: 0.5 mM 3-isobutyl-1-methylxanthine, 1 µg/mL insulin, 0.25 µM dexamethasone (Sigma-Aldrich, St Louis, MO, USA), and 2 µM rosiglitazone (Cayman Chemical, Ann Arbor, MI, USA). After 48 hours (day 3), the media were changed to fresh basal media containing 1 µg/mL insulin. After a further 48 hours (day 5), media were changed back to fresh basal media and cells grown for 7 days under these conditions with new media every 2 days. On day 12, cells were washed with phosphate-buffered saline (PBS) and media were changed to serum-free Opti-MEM (Thermo Fisher). After further 24 hours (day 13), media were replaced with serum-free Opti-MEM along with the previously mentioned concentrations of CS, without and with 1 µg/mL LPS (Enzo Life Sciences, Farmingdale, NY, USA). After a further 24 hours (day 14), cell viability was measured for each well using PrestoBlue Cell Viability Reagent (Thermo Fisher) and media were tested for assay interference. All experiments were run a single time with each treatment group run in triplicate.

**THP-1 monocyte experiments**

The THP-1 human monocytic cell line was obtained from ATCC and was grown at 5% CO₂ in RPMI 1640 with HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) and supplemented with glucose, pyruvate, 2-mercaptoethanol, 10% fetal bovine serum, and penicillin/streptomycin as recommended by ATCC (media and supplements from Thermo Fisher). Cells were washed in PBS and the media changed to serum-free Opti-MEM supplemented with 0.5% bovine serum albumin (Sigma-Aldrich). After 24 hours, cells were resuspended at a density of 1.25 × 10⁶ cells/mL in the same media, with and without 200 µg/mL CS. Monocyte chemotaxis in response to 24-hour exposure to varying concentrations (0, 1.25 × 10⁴ to 100 ng/mL) of recombinant human MCP-1 (R&D Systems) was tested using the CytoSelect 96-well Cell Migration Assay (Cell Biolabs, San Diego, CA, USA). All experiments were run a single time with each treatment group run in triplicate.

**Statistical analysis**

After normalization for cell viability, cell culture results were expressed as fold change from the media-only negative control (no CS, no LPS). One-way analysis of variance with Bonferroni post hoc test and post hoc linear trend was performed on cell culture results. Unpaired t test was used to assess the effect of LPS on cell viability, and paired t test was used to determine whether CS interfered the MCP-1 ELISA. GraphPad Prism software (La Jolla, CA, USA) was used for all analyses.

**Results**

Lipopolysaccharide (1 µg/mL) caused a significant rise in MCP-1 release (P < 0.001, 95% confidence interval [CI]: 3.911-5.069) from 3T3-L1 adipocytes. Chondroitin sulfate in physiologically achievable concentrations (100-200 µg/mL) produced a dose-dependent reduction (P < .01, 95% CI: −5.89 to −3.858 at 100 µg/mL, and P = .9784, 95% CI: −3.996 to 200 µg/mL) of MCP-1 release from 3T3-L1 adipocytes in response to LPS (Figure 1). Cell viability between control and LPS-only groups was unaffected (P = .30, 95% CI: −2333 to 5843) by this dose of LPS (Figure 2). Chondroitin sulfate showed no interference with the MCP-1 ELISA (P = .78, 95% CI: −5.127 to 4.030), producing a standard curve spiked with 200 µg/mL of CS that was identical to an unspiked standard curve (Figure 3). Recombinant MCP-1 (25-100 ng/mL) caused a dose-dependent increase (P < .001, 95% CI: 0.1896-0.5949 at 25 ng/mL and P < .001, 95% CI: 2.786-3.192 at 100 ng/mL) in cell migration of THP-1 monocytes. Chondroitin sulfate at the highest test concentration (200 µg/mL) had no effect on MCP-1-mediated THP-1 migration (Figure 4).

**Discussion**

It is well established that the binding of activated NF-κB to the MCP-1 gene promoter is a key step in the upregulation of...
MCP-1 gene expression.\textsuperscript{4,5} The activation of NF-κB can occur through many receptors including the interleukin-1 receptor, the TNF receptor, and toll-like receptors, such as TLR4, which LPS activate. Although it is still unclear exactly where CS is acting to inhibit NF-κB, whether on its activation\textsuperscript{11} or on the nuclear translocation of the activated form,\textsuperscript{12} the inhibition by CS at either point would be expected to reduce the production of MCP-1. The effects of CS on gene expression, at the RNA level and the protein level, have been extensively studied in cells and tissues associated with osteoarthritis, including chondrocytes, synovial fibroblasts, and synovial membrane.\textsuperscript{15–17} Although CS has been found effective in reducing the production of various inflammatory proteins in these studies, no study has looked at the effect of CS in adipocytes.

**Conclusions**

Our data demonstrate that CS inhibits the release of MCP-1 from 3T3-L1 adipocytes that have been stimulated with LPS but has no effect on the chemotactic action of MCP-1 on THP-1 monocytes. It has recently been demonstrated that CS can inhibit the release of MCP-1 from human coronary artery endothelial cells inflamed by TNF-α; in this model system, CS also inhibited the migration of THP-1 monocytes toward the inflamed HCAECs.\textsuperscript{18} Our data strongly suggest that it is the inhibition of MCP-1 release by CS that underlies this effect and not a direct inhibition of the chemotactic action of MCP-1 by CS. Although it is unclear whether CS might accumulate sufficiently in adipose tissue in vivo to have an effect,\textsuperscript{19} given the in vivo relevance of LPS\textsuperscript{20} and importance
of MCP-1 overproduction in obesity-related metabolic syndromes, inhibiting the release of MCP-1 from adipocytes by CS, and thus blocking the recruitment of macrophages to adipose tissue, could provide a new treatment opportunity for these syndromes. Because CS is so well tolerated and readily accessible, it might provide a safe and clinically effective treatment for reducing inflammation in obesity–related syndromes. Although the more relevant end product of transcription, ie, the translated protein, was studied here, gene expression studies might be a useful future avenue of research. This in vitro work establishes the rationale for evaluation of MCP-1 modulation in future in vivo studies of CS.

Author Contributions
TVS conducted most experiments, participated in the design of the study, performed the statistical analysis, and drafted the manuscript. EM participated in the design of the study and manuscript preparation. All authors read and approved the final version of the manuscript.

REFERENCES
1. Melgarejo E, Medina MA, Sanchez-Jimenez F, Urdiales JL. Monocyte chemoattractant protein-1: a key mediator in inflammatory processes. Int J Biochem Cell Biol. 2009;41:998–1001.
2. Panee J. Monocyte chemoattractant protein 1 (MCP-1) in obesity and diabetes. Cytokine. 2012;60:1–12.
3. Cullberg KB, Larsen JO, Pedersen SB, Richelsen B. Effects of LPS and dietary free fatty acids on MCP-1 in 3T3-L1 adipocytes and macrophages in vitro. Nutr Diabetes. 2014;4:e113.
4. Ueda A, Okuda K, Ohno S, et al. NF-kappa B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. J Immunol. 1994;153:2052–2063.
5. Ueda A, Ishigatsu Y, Okubo T, Yoshimura T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem. 1997;272:31092–31099.
6. Ab Wahab SM, Gebhardt R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 2017;91:1545–1563.
7. Huber Y, Gelukke N, Biedenbach J, et al. Voluntary distance running prevents TNF-mediated liver injury in mice through alterations of the intrahepatic immune milieu. Cell Death Dis. 2017;8:e2893.
8. Ab Wahab SM, Xu M, Seyer HA, et al. Diet high in fructose leads to an overexpression of lipocalin-2 in rat fatty liver. World J Gastroenterol. 2014;20:1807–1821.
9. du Souich P. Absorption, distribution and mechanism of action of SYSADOAS. Pharmacol Ther. 2014;142:362–374.
10. Orlowsky EW, Stabler TV, Montell E, Verges J, Kraus VB. Monosodium urate crystal induced macrophage inflammation is attenuated by chondroitin sulphate: pre-clinical model for gout prophylaxis? BMC Musculoskelet Disord. 2014;15:318.
11. Stabler TV, Huang Z, Montell E, Verges J, Kraus VB. Chondroitin sulphate inhibits NF-kB activity induced by interaction of pathogenic and damage associated molecules. Osteoarthritis Cartilage. 2017;25:166–174.
12. Jompe C, Gabriac M, Hale TM, et al. Chondroitin sulfate inhibits the nuclear translocation of nuclear factor-kappaB in interleukin-1beta-stimulated chondrocytes. Basic Clin Pharmacol Toxicol. 2008;102:59–65.
13. Zebisch K, Voigt V, Wabitsch M, Brandsch M. Protocol for effective differentiation of 3T3-L1 cells to adipocytes. Anal Biochem. 2012;425:88–90.
14. Homandberg GA, Guo D, Ray LM, Ding L. Mixtures of glucosamine and chondroitin sulfate reverse fibronectin fragment mediated damage to cartilage more effectively than either agent alone. Osteoarthritis Cartilage. 2006;14:793–806.
15. Lambert C, Mathy-Harrett M, Dubeuc JE, et al. Characterization of synovial angiogenesis in osteoarthritic patients and its modulation by chondroitin sulfate. Arthritis Res Ther. 2012;14:R58.
16. Calamia V, Lourido L, Fernandez-Puente P, et al. Secretome analysis of chondroitin sulfate–treated chondrocytes reveals anti-angiogenic, anti-inflammatory and anti-catabolic properties. Arthritis Res Ther. 2012;14:R202.
17. Calamia V, Ruiz-Romero C, Rocha B, et al. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res Ther. 2010;12:R138.
18. Melgar-Lesmes P, Garcia-Polite F, Del-Rey-Puech P, et al. Treatment with chondroitin sulfate to modulate inflammation and atherogenesis in obesity. Atherosclerosis. 2016;245:82–87.
19. Ronca F, Palmieri L, Panicucci P, Ronca G. Anti-inflammatory activity of chondroitin sulfate. Osteoarthritis Cartilage. 1998;6:14–21.
20. Huang Z, Kraus VB. Does lipopolysaccharide-mediated inflammation have a role in OA? Nat Rev Rheumatol. 2016;12:123–129.